Teva Pharmaceutical Industrices has announced its second generic drug launch, receiving marketing approval by the US Food and Drug Administration (FDA) for its generic version of Kytril, an anti-nausea, anti-vomiting treatment made by Roche. Kytril is typically presecribed to chemotherapy patients who suffer side effects from cancer treatments.
As the first company to file an Abbreviated New Drug Applications (ANDA) with patent certification for generic Kytril, Teva will have a 180-day exclusivity period. Teva has begun work on producing a generic version of DuoNeb, a bronchodilator made by Dey LP.
Kytril sold a total of $123 million worth of medication in the US in 2007.